Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624528 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
A Phase 2 study of Obsessive - Compulsive Disorder and OCD, sponsored by University of Chicago.
- Active
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT05624528: Active Phase 2 study of Obsessive - Compulsive Disorder and OCD, sponsored by University of Chicago.
NCT05624528 is a Phase 2 study of Obsessive - Compulsive Disorder and OCD that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 49 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05624528, a Phase 2 study of Obsessive - Compulsive Disorder and OCD, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
Primary Outcome
A measure of OCD illness severity
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tolcapone
Study Locations (1)
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2023-06-22 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT05624528 still lists
NCT05624528 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05624528 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05624528 about?
NCT05624528 is a clinical study titled "A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder". The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
What is the current status of trial NCT05624528?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2023-06-22. Estimated completion is 2026-06.
What conditions does trial NCT05624528 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder, OCD.
What interventions are being tested in trial NCT05624528?
The interventions under investigation include: Placebo (DRUG), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT05624528?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05624528 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05624528's enrollment target sits among peer trials
49 43rd of 84 higher than 42 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
RECRUITING · Phase 2
-
Efficacy of Nitrous Oxide in OCD: Pilot Study
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
RECRUITING · Phase 2
-
Study of Dextromethorphan in OCD and Related Disorders
RECRUITING · Phase 2
-
Understanding How Ketamine Brings About Rapid Improvement in OCD
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI